perifosine has been researched along with Benign Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MM; Joh, EH; Kim, B; Kim, DH; Lee, YS; Park, H | 1 |
| Gaillard, B; Lebeau, L; Pons, F; Remy, JS | 1 |
| Cartagena-Rivera, AX; Chadwick, RS; Logue, JS | 1 |
| Aicher, B; Engel, J; Fensterle, J; Seipelt, I; Teifel, M | 1 |
| Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A | 1 |
| Friedman, DR; Hagiopian, MM; Holohan, B; Huang, E; Lai, TP; Shay, JW; Wright, WE | 1 |
| van Blitterswijk, WJ; Verheij, M | 2 |
| Dennis, PA; Gills, JJ | 1 |
| Cseh, A; Szalay, B; Szebeni, B; Vásárhelyi, B | 1 |
| Berdel, W; Engel, J; Hanauske, AR; Mross, K; Sindermann, H; Unger, C | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Beijnen, JH; Crul, M; de Klerk, GJ; Dubbelman, R; Knebel, NG; Reichert, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; Traiser, M | 1 |
| Alberti, D; Arzoomanian, R; Binger, K; Kolesar, J; Marnocha, R; Tutsch, K; Van Ummersen, L; Volkman, J; Wilding, G | 1 |
| Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R | 1 |
| Bartelink, H; Beijnen, JH; Dubbelman, R; Engel, J; Hillebrand, MJ; Moppi, G; Schellens, JH; Sindermann, H; Verheij, M; Vink, SR | 1 |
| Birch, R; Carey, MS; Gonzalez-Angulo, AM; Hall, H; Henderson, IC; Hennessy, BT; Kundra, V; Lu, Y; Mills, GB; Poradosu, E; Ravoori, M; Yu, Q; Yu, S | 1 |
5 review(s) available for perifosine and Benign Neoplasms
| Article | Year |
|---|---|
Current view on the mechanism of action of perifosine in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Humans; Lipid Metabolism; Membrane Microdomains; Neoplasms; Neoplastic Stem Cells; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptors, Death Domain; Signal Transduction | 2014 |
Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Neoplasms; Phospholipid Ethers; Phosphorylcholine; Signal Transduction | 2008 |
Perifosine: update on a novel Akt inhibitor.
Topics: Animals; Clinical Trials as Topic; Humans; Membrane Microdomains; Neoplasms; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2009 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Anticancer mechanisms and clinical application of alkylphospholipids.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Endocytosis; Humans; Neoplasms; Organophosphates; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quaternary Ammonium Compounds; Signal Transduction | 2013 |
6 trial(s) available for perifosine and Benign Neoplasms
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phosphorylcholine; Treatment Outcome; Young Adult | 2014 |
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Topics: Abdominal Pain; Administration, Oral; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Phosphorylcholine; Treatment Outcome; Vomiting | 2010 |
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Maximum Allowable Concentration; Middle Aged; Neoplasms; Phosphorylcholine | 2002 |
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Phosphorylcholine; Serotonin 5-HT3 Receptor Antagonists; Signal Transduction; Time Factors; Treatment Outcome | 2004 |
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Phosphorylcholine; Sarcoma | 2006 |
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Phosphorylcholine; Radiation-Sensitizing Agents | 2006 |
7 other study(ies) available for perifosine and Benign Neoplasms
| Article | Year |
|---|---|
Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines.
Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Neoplasms; Phospholipid Ethers; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2013 |
Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs.
Topics: Administration, Intravenous; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Stability; Hemolysis; Humans; Maximum Tolerated Dose; Neoplasms; Organophosphates; Phosphorylcholine; Prodrugs; Quaternary Ammonium Compounds | 2020 |
c-Src activity is differentially required by cancer cell motility modes.
Topics: Actins; Amino Acid Substitution; Butadienes; Cell Adhesion; Cell Movement; Dasatinib; Humans; Imidazoles; Mutant Proteins; Neoplasms; Nitriles; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinolines; Tumor Cells, Cultured | 2018 |
Perifosine as a potential novel anti-telomerase therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Phosphorylcholine; Telomerase; Telomere; Xenograft Model Antitumor Assays | 2015 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin Resistance; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Ribonucleosides | 2009 |
ACCESS oncology and Zentaris sign product partnership.
Topics: Clinical Trials, Phase II as Topic; Cooperative Behavior; Drug Industry; Humans; Neoplasms; Phosphorylcholine | 2002 |
Pharmacodynamic markers of perifosine efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; Immunoblotting; Mice; Mice, Nude; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Transfection; Xenograft Model Antitumor Assays | 2007 |